IRON

#1686
Disc Medicine, Inc. - Common Stock
80.0 5 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
80.05
80.05
Intervallo Annuale
40.00
99.50
Variazione giornaliera
+1.75%
Variazione Mensile
+4.53%
Variazione di 6 mesi
+23.48%
Variazione Annuale
+29.97%
Chiusura Precedente
78.6 7
Open
80.0 5
Minimo
80.0 5
Massimo
80.0 5
Volume
119
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Disc Medicine, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Disc Medicine, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Disc Medicine, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Disc Medicine, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Disc Medicine, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Disc Medicine, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K

Disc Medicine, Inc. current report, Q4 FY2023

Full document

Business Context and Reporting Period

Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2023
Reporting Period: The filing announces financial results for the quarter ended September 30, 2023, and provides a corporate update.

Key Financial Metrics

The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:

  • Revenue: Not provided in filing text.
  • Profit/Loss: Not provided in filing text.
  • Cash Flow: Not provided in filing text.
  • Margins: Not provided in filing text.
  • Debt and Liquidity: Not provided in filing text.

Material Changes

The filing text does not detail specific material changes versus the prior comparable period. It serves only to notify investors that results for the quarter ended September 30, 2023, have been announced.

Guidance, Outlook, and Risks

Management Commentary: The company provided a corporate update alongside the financial results, but the specific content of this update is not included in the filing text.
Legal Status of Information: The information in Item 2.02 and the attached press release is deemed "furnished" and not "filed" under the Exchange Act. It is not subject to Section 18 liabilities nor incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the quarter ended September 30, 2023.
  • Verify the specific details of the "corporate update" mentioned in the filing, as the text does not summarize operational milestones or pipeline progress.
  • Confirm the company's status as an Emerging Growth Company (indicated as checked in the filing) and its implications for financial reporting standards.
  • Check subsequent filings for any updates to the guidance or outlook provided in the November 9, 2023 press release.

Notizie